Equities research analysts predict that aTyr Pharma Inc (NASDAQ:LIFE) will post ($0.21) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for aTyr Pharma’s earnings. aTyr Pharma posted earnings per share of ($0.36) in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.7%. The company is expected to report its next earnings report on Monday, May 13th.

According to Zacks, analysts expect that aTyr Pharma will report full year earnings of ($0.80) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($0.99) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for aTyr Pharma.

aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings results on Monday, March 25th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01.

LIFE has been the topic of several recent analyst reports. Zacks Investment Research lowered aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. ValuEngine upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, William Blair reiterated a “market perform” rating on shares of aTyr Pharma in a research note on Tuesday, March 26th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. aTyr Pharma has a consensus rating of “Buy” and a consensus target price of $1.01.

An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC raised its stake in aTyr Pharma Inc (NASDAQ:LIFE) by 107.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,107,025 shares of the biotechnology company’s stock after buying an additional 573,164 shares during the period. Renaissance Technologies LLC owned about 3.71% of aTyr Pharma worth $899,000 as of its most recent SEC filing. 30.47% of the stock is currently owned by institutional investors and hedge funds.

Shares of LIFE traded up $0.01 during midday trading on Friday, hitting $0.55. The company’s stock had a trading volume of 50,326 shares, compared to its average volume of 384,652. aTyr Pharma has a one year low of $0.38 and a one year high of $2.60. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.69 and a current ratio of 4.69. The firm has a market cap of $20.00 million, a price-to-earnings ratio of -0.48 and a beta of 2.45.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Featured Article: Recession

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.